Login / Signup

Cost-effectiveness of sleeping sickness elimination campaigns in five settings of the Democratic Republic of Congo.

Marina AntillónChing-I HuangRonald E CrumpPaul E BrownRian SnijdersErick Mwamba MiakaMatt J KeelingKat S RockFabrizio Tedisio
Published in: Nature communications (2022)
Gambiense human African trypanosomiasis (gHAT) is marked for elimination of transmission by 2030, but the disease persists in several low-income countries. We couple transmission and health outcomes models to examine the cost-effectiveness of four gHAT elimination strategies in five settings - spanning low- to high-risk - of the Democratic Republic of Congo. Alongside passive screening in fixed health facilities, the strategies include active screening at average or intensified coverage levels, alone or with vector control with a scale-back algorithm when no cases are reported for three consecutive years. In high or moderate-risk settings, costs of gHAT strategies are primarily driven by active screening and, if used, vector control. Due to the cessation of active screening and vector control, most investments (75-80%) are made by 2030 and vector control might be cost-saving while ensuring elimination of transmission. In low-risk settings, costs are driven by passive screening, and minimum-cost strategies consisting of active screening and passive screening lead to elimination of transmission by 2030 with high probability.
Keyphrases
  • healthcare
  • public health
  • endothelial cells
  • health insurance
  • health promotion